Navigation Links
Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President
Date:7/30/2014

WESTFORD, Mass., July 30, 2014 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO), a leader in laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, today announced that the Board of Directors has promoted Executive Vice President, Chief Operating Officer and Chief Financial Officer Timothy W. Baker to President of the Company, effective August 1, 2014.  Baker, 53, will continue to serve as CFO and will take the title of President from Michael Davin, who remains Chairman and Chief Executive Officer.

"Tim has been a valued member of Cynosure's leadership team since joining the Company as Executive Vice President and CFO in 2004," Davin said. "He is focused on continuously improving our financial and operating performance and committed to delivering value for our shareholders. Tim played a key strategic role in our June 2013 acquisition of Palomar Medical Technologies; his operational skills and business expertise were keys to successfully completing the integration in just 12 months. We congratulate Tim on this well-deserved promotion."

Before joining Cynosure, Baker served as Vice President, Finance at Stryker Biotech, a division of medical products and services provider Stryker Corporation. From July 2000 to June 2003, Baker served as President and Chief Financial Officer at Photoelectron Corp., a provider of miniature X-ray systems for radiation therapy. From January 1996 to July 2000, he served as Chief Financial Officer and Vice President of Operations at Radionics, Inc., a provider of surgical devices. Baker is a certified public accountant and holds an MBA in operations management.

About Cynosure, Inc.

Cynosure develops and markets laser and light-based aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands.  Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light.  Cynosure sells its products globally under the Cynosure, Palomar and ConBio brand names through a direct sales force in the United States, Canada, Mexico, France, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 120 other countries.  For corporate or product information, visit Cynosure's website at www.cynosure.com.

Contact
Scott Solomon
Vice President
Sharon Merrill Associates
617-542-5300
cyno@investorrelations.com

Photo - http://photos.prnewswire.com/prnh/20140729/130910


'/>"/>
SOURCE Cynosure, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Cynosure Reports Second-Quarter 2014 Financial Results
2. Cynosure to Present at 16th Annual Needham Growth Conference
3. Cynosure Announces Successful Settlement of Patent Infringement Lawsuits Against Tria Beauty
4. Cynosure Announces Sale of Burlington, MA Office Building
5. Cynosure Reports Third-Quarter 2013 Financial Results
6. Cynosure Completes Acquisition of Palomar Medical Technologies
7. Cynosure Added to the S&P SmallCap 600 Index
8. Cynosure to Present at UBS Global Healthcare Conference
9. Cynosure Reports First-Quarter 2013 Financial Results
10. Cynosure Announces Presentation of 16 Abstracts at 33rd ASLMS Annual Conference
11. Cynosure Reports Record Revenues for Fourth-Quarter and Full-Year 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... 7, 2017  Novavax, Inc., (Nasdaq: NVAX ) ... 2 trials of its RSV F protein recombinant nanoparticle vaccine ... have been published in the journal Vaccine ... in prior scientific conferences). The Company previously announced top ... is developing the RSV F Vaccine with the goal of ...
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
(Date:5/29/2017)... -- Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: APOP), ... selection of stem cells, today provided a corporate update ... March 31 st , 2017. "We ... quarter of 2017," said Dr. Shai Yarkoni, Chief Executive ... of the first blood cancer patient in the recently ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... 2017 , ... CareSet Labs released the Root NPI Graph today at the ... greatly improved version of the Doctor Referral teaming dataset commonly available from Medicare. , ... called the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as released ...
(Date:6/24/2017)... , ... June 24, 2017 , ... ... Erie, PA at the Sheraton Erie Bayfront and Erie Convention Center on June ... medicine experience, exhibits, a student quiz bowl, award and scholarship presentations, and professional ...
(Date:6/23/2017)... Providence, RI (PRWEB) , ... June 23, 2017 ... ... Community Care Network today announced the launch of Care Management Alerts and Dashboards, ... for 140,000 patients throughout Rhode Island. , RIQI’s Care Management Alerts and Dashboards ...
(Date:6/23/2017)... ... , ... Studies show evidence that carotenoids and antioxidants derived either from the ... patients. , But how often do ophthalmologists and optometrists in Sweden recommend the use ... or with early symptoms of AMD? A study published recently in Dove ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal ... prefer to read it, and some people don't like it at all. FindaTopDoc took ... they found: , Erotic literature can give readers a taste of their deepest, darkest ...
Breaking Medicine News(10 mins):